Distinguished in Gliosarcoma

Dr. Joseph C. Landolfi

Neurology
Hackensack Meridian Health Medical Group - Specialty Care PC
65 James St, 
Edison, NJ 
Distinguished in Gliosarcoma
Hackensack Meridian Health Medical Group - Specialty Care PC
65 James St, 
Edison, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Landolfi is a Neurologist in Edison, New Jersey. Dr. Landolfi is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Glioblastoma, and Astrocytoma.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Gliosarcoma.

Specialties
Neurology
Licenses
Psychiatry & Neurology in NJ
Hospital Affiliations
Jfk University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
65 James St, Edison, NJ 08820

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive Glioblastoma
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive Glioblastoma
Enrollment Status: Terminated
Publish Date: April 18, 2025
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

9 Total Publications

NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics.
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics.
Journal: Neuro-oncology advances
Published: January 23, 2023
Similar Doctors
Elite in Gliosarcoma
Dr. Deric Park
Neurology | Hematology | Oncology
Elite in Gliosarcoma
Dr. Deric Park
Neurology | Hematology | Oncology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (27.5 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances

Deric Park is a Neurologist and a Hematologist in Hackensack, New Jersey. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Gliosarcoma, Astrocytoma, Glioblastoma, and Glioma.

Distinguished in Gliosarcoma
Dr. Robert Aiken
Neurology
Distinguished in Gliosarcoma
Dr. Robert Aiken
Neurology

Practice Associates Medical Group

99 Beauvoir Ave, 
Summit, NJ 
 (10.7 miles away)
908-522-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Aiken is a Neurologist in Summit, New Jersey. Dr. Aiken is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliosarcoma.

Distinguished in Gliosarcoma
Dr. Fabio M. Iwamoto
Neurology
Distinguished in Gliosarcoma
Dr. Fabio M. Iwamoto
Neurology

Trustees Of Columbia University In The City Of New York

710 W 168th St, 
New York, NY 
 (29.1 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fabio Iwamoto is a Neurologist in New York, New York. Dr. Iwamoto is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Landolfi's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile